Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
E6011 in Active Crohn's Disease
NCT03733314Phase 2Completed
- Sponsor
- EA Pharma Co., Ltd.
- Start
- Apr 2019
- Primary completion
- Mar 2022
- Modality
- Monoclonal Antibodies
- Countries
- 5
01
Overview
Phase 2, randomised, double-blind trial in Crohn's disease comparing E6011 with Placebo (2 arms). Primary endpoint: Clinical Response 100 at 12 weeks. Started Apr 2019; status: completed.
02
Drugs
quetmolimab
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NCT03733314.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03733314.